Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

10.02.25 22:10 Uhr

Werte in diesem Artikel
Aktien

29,40 EUR -0,40 EUR -1,34%

ATLANTA, Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

(PRNewsfoto/Artivion, Inc.)

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13749878. 

The live webcast and replay can be accessed on the Investors section of the Artivion website at www.artivion.com and by selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investors section of the Artivion website.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:


Artivion

Lance A. Berry

Executive Vice President &

Chief Financial Officer
Phone: 770-419-3355

Gilmartin Group LLC

Brian Johnston / Laine Morgan
Phone: 332-895-3222

investors@artivion.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-release-date-and-teleconference-call-details-for-fourth-quarter-and-full-year-2024-financial-results-302372746.html

SOURCE Artivion, Inc.

Ausgewählte Hebelprodukte auf CryoLife

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf CryoLife

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu CryoLife Inc.

Wer­bung

Analysen zu CryoLife Inc.

DatumRatingAnalyst
28.02.2019CryoLife HoldNeedham & Company, LLC
15.06.2016CryoLife BuyLake Street
13.04.2016CryoLife BuyCanaccord Adams
24.04.2012CryoLife buyLadenburg Thalmann & Co. Inc.
18.09.2006Cryolife für CharttechnikerGlobal Biotech Investing
DatumRatingAnalyst
15.06.2016CryoLife BuyLake Street
13.04.2016CryoLife BuyCanaccord Adams
24.04.2012CryoLife buyLadenburg Thalmann & Co. Inc.
18.09.2006Cryolife für CharttechnikerGlobal Biotech Investing
DatumRatingAnalyst
28.02.2019CryoLife HoldNeedham & Company, LLC
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CryoLife Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"